Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Intima Bioscience

Main focus: Next generation cell therapies for solid tumours

Company stage: Clinical

Diseases: Multiple solid tumours

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: New York, USA

Website: https://www.intimabioscience.com/

Intima Bioscience is a clinical-stage gene and cell therapy company focused on developing cures for solid cancers. The company develops tumour-infiltrating lymphocytes (TILs) in which the novel cytokine checkpoint CISH is disrupted using CRISPR. The company is currently testing its lead programme in multiple solid tumours in a Phase 1/2 clinical trial.

Intima Bioscience, Inc.

Press Releases

Related News and Updates

Job Opportunities

Clinical Trials

Pre-clinical Trials

Stocks and Markets

Diseases

Webinar

Your Latest CMN News

CMN Weekly (21 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 21, 2025

Some of the best links we picked up around the internet

Bahrain Reports First Administration of CASGEVY in...

Feb. 19, 2025

The Bahrain Oncology Centre announced a major milestone on Sunday with the successful administration of CASGEVY - the world's only approved therapy...

CRISPR–Csm enables single-molecule RNA imaging in...

CMN Briefs

Feb. 18, 2025

A new technique developed by Jennifer Doudna and colleagues at the University of California, Berkeley, achieves single-molecule resolution imaging of...

CRISPR screen links BAF mutation to premature...

CMN Briefs

Feb. 17, 2025

A genome-wide CRISPR screen in fibroblasts from patients with Néstor-Guillermo Progeria Syndrome (NGPS) identified 43 genes that mitigate multiple...

CMN Weekly (14 February 2025) - Your Weekly CRISPR...

CMN Weekly

Feb. 14, 2025

Some of the best links we picked up around the internet

FDA Grants Dual Designations to Arbor's Gene...

CMN Clinical

Feb. 12, 2025

The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for...